These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16699265)

  • 1. CCK1 antagonists: are they ready for clinical use?
    Peter SA; D'Amato M; Beglinger C
    Dig Dis; 2006; 24(1-2):70-82. PubMed ID: 16699265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Applicability of CCK receptor antagonists in physiologic and therapeutic studies].
    Heintges T; Niederau C
    Z Gastroenterol; 1992 May; 30(5):337-43. PubMed ID: 1632116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of luminal gastrin in the regulation of pancreatic juice secretion in preruminant calves.
    Zabielski R; Normand V; Romé V; Woliński J; Chayvialle JA; Guilloteau P
    Regul Pept; 2004 Jul; 119(3):169-76. PubMed ID: 15120477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholecystokinin antagonists: pharmacological and therapeutic potential.
    Herranz R
    Med Res Rev; 2003 Sep; 23(5):559-605. PubMed ID: 12789687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of endogenous CCK and CCK1 receptors in colonic motor function.
    Varga G; Bálint A; Burghardt B; D'Amato M
    Br J Pharmacol; 2004 Apr; 141(8):1275-84. PubMed ID: 15100163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral apelin-13 administration inhibits gastrointestinal motor functions in rats: The role of cholecystokinin through CCK
    Bülbül M; Sinen O; Birsen İ; Izgüt-Uysal V
    Neuropeptides; 2017 Jun; 63():91-97. PubMed ID: 28012561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Medicamentous modification of gastrointestinal motility and secretion].
    Allescher HD
    Z Gastroenterol; 1991 Apr; 29 Suppl 3():27-30. PubMed ID: 1648290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [On the possibility of using prokinetics in gastroenterology].
    Sheptulin AA; Vize-Khripunova MA
    Klin Med (Mosk); 2010; 88(5):19-22. PubMed ID: 21089451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCK1 and 2 receptors are expressed in immortalized rat brain neuroblasts: intracellular signals after cholecystokinin stimulation.
    Langmesser S; Cerezo-Guisado MI; Lorenzo MJ; Garcia-Marin LJ; Bragado MJ
    J Cell Biochem; 2007 Mar; 100(4):851-64. PubMed ID: 17226751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cholecystokinin in appetite control and body weight regulation.
    Little TJ; Horowitz M; Feinle-Bisset C
    Obes Rev; 2005 Nov; 6(4):297-306. PubMed ID: 16246215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholecystokinin: role in thermoregulation and other aspects of energetics.
    Szelényi Z
    Clin Chim Acta; 2010 Mar; 411(5-6):329-35. PubMed ID: 20036221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different pathways mediated by CCK1 and CCK2 receptors: effect of intraperitonal mrna antisense oligodeoxynucleotides to cholecystokinin on anxiety-like and learning behaviors in rats.
    Cohen H; Kaplan Z; Matar MA; Buriakovsky I; Bourin M; Kotler M
    Depress Anxiety; 2004; 20(3):139-52. PubMed ID: 15487014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological targets in gastro-oesophageal reflux disease.
    Piche T; Galmiche JP
    Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):333-41. PubMed ID: 16364047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tachykinin receptors as drug targets for motility disorders.
    Hoogerwerf WA; Sarna SK
    Dig Dis; 2006; 24(1-2):83-90. PubMed ID: 16699266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gastrointestinal motility disorders and drugs: cholinergic, anticholinergic, adrenergic, antiadrenergic and prokinetic drugs (part I)].
    Jovanović-Mićić D; Janković S; Beleslin DB
    Srp Arh Celok Lek; 1994; 122(1-2):50-4. PubMed ID: 17972806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gastrointestinal motility disorders and drugs: opioids, calcium antagonists, nitrates, peptides, prostaglandins and 5-hydroxytryptaminergic drugs (part II)].
    Jovanović-Mićić D; Samardzić R; Beleslin B
    Srp Arh Celok Lek; 1994; 122(3-4):88-92. PubMed ID: 17972818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated actions of cholecystokinin on the gastrointestinal tract: use of the cholecystokinin bioassay.
    Liddle RA
    Gastroenterol Clin North Am; 1989 Dec; 18(4):735-56. PubMed ID: 2482253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.
    Bignon E; Bachy A; Boigegrain R; Brodin R; Cottineau M; Gully D; Herbert JM; Keane P; Labie C; Molimard JC; Olliero D; Oury-Donat F; Petereau C; Prabonnaud V; Rockstroh MP; Schaeffer P; Servant O; Thurneyssen O; Soubrié P; Pascal M; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1999 May; 289(2):742-51. PubMed ID: 10215648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCK2 receptors mediate inhibitory effects of cholecystokinin on the motor activity of guinea-pig distal colon.
    Fornai M; Colucci R; Antonioli L; Baschiera F; Ghisu N; Tuccori M; Gori G; Blandizzi C; Del Tacca M
    Eur J Pharmacol; 2007 Feb; 557(2-3):212-20. PubMed ID: 17208221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of prolonged cholecystokinin administration on rat pituitary-adrenocortical axis: role of the CCK receptor subtypes 1 and 2.
    Malendowicz LK; Spinazzi R; Majchrzak M; Nowak M; Nussdorfer GG; Ziolkowska A; Macchi C; Trejter M
    Int J Mol Med; 2003 Dec; 12(6):903-9. PubMed ID: 14612964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.